Peanut allergy could plummet by 77 percent if peanut products were added to all babies’ diets at four to six months of age, according to new research led by the University of Southampton, Kings College London, and the National Institute for Health and Care Research (NIHR).

Click on the article title to read more.

Mice experienced far fewer hay fever symptoms when a pollen-blocking antibody was applied within their nose

Food allergy, a group of adverse immune responses to normally innocuous food protein antigens, is an increasingly prevalent public health issue. The most com...

Click on the article title to read more.

Find out more about the award!

Estimated reading time: 7 minutes Researchers at Massachusetts General Hospital have uncovered the reason why some people experience more intense itching

Allergic inflammation is closely related to the activation of mast cells (MCs), which is regulated by its intracellular Ca2+ level, but the intake and…

First clinical trial of its kind could be ‘life changing’ for those living in fear of severe peanut reaction Adults with severe peanut allergies can be desensitised by daily exposure, according to...

A study at Mount Sinai has shown that children with a high tolerance for peanuts can significantly increase their resistance to allergic reactions by consuming controlled, increasing amounts of peanut...

Skin injury releases damage-encoded systemic signals that can initiate immunity to novel antigens introduced at distal barrier sites.

Study reveals significant impairments in the quality of life for adults with hen's egg white allergy, highlighting the need for accurate food labeling and further research into effective treatments.

Plants are composed of diverse secondary metabolites. Here, we discover members of the human gut microbiome that have evolved enzymes to metabolize specific dietary phenolic small molecules that activ...

Investing.com -- Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced positive results from two Phase 3 trials evaluating first-in-class antibody-blockers targeting cat and birch allergies. The pharmaceutical company reported that both trials successfully met their primary and secondary endpoints. The combination therapy was well-tolerated with no serious adverse events reported during the studies. Following these encouraging results, Regeneron plans to advance its allergy pipeline with additional Phase 3 development scheduled to begin in the first half of 2026. The trials represent progress in Regeneron’s efforts to develop novel treatments for common allergies using antibody-blocking technology, potentially offering new options for allergy sufferers. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. 3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads. Is REGN part of an AI-powered winning strategy? ProPicks AI evaluates REGN alongside thousands of other companies every month using 100+ financial metrics. Using powerful AI to generate exciting stock ideas, it looks beyond popularity to assess fundamentals, momentum, and valuation. The AI has no bias—it simply identifies which stocks offer the best risk-reward based on current data with notable past winners that include Super Micro Computer (+185%) and AppLovin (+157%). Want to know if REGN is currently featured in any ProPicks AI strategies, or if there are better opportunities in the same space?